An engineered non-toxic superantigen increases cross presentation of hepatitis B virus nucleocapsids by human dendritic cells

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  McIntosh, Julie D ^a   Manning, Kristy ^a   Chokshi, Shilpa ^c   Naoumov, Nikolai V ^c,d   Fraser, John D ^b   Dunbar, P Rod ^a   Taylor, John A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MAURICE WILKINS CENTRE FOR MOLECULAR BIODISCOVERY   (New Zealand)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; HEPATITIS B CORE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN SMEZ2; SUPERANTIGEN; UNCLASSIFIED DRUG; BACTERIAL TOXIN; EXOTOXIN; MITOGENIC EXOTOXIN Z PROTEIN, STREPTOCOCCUS; VIRUS LIKE PARTICLE VACCINE;

ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; COVALENT BOND; CROSS PRESENTATION; DENDRITIC CELL; ENDOCYTOSIS; ENDOSOME; HELPER CELL; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE ACTIVATION; VIRUS LIKE AGENT; VIRUS NUCLEOCAPSID; GENETICS; HEPATITIS B; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOGENICITY; VIROLOGY;

ANTIGEN-PRESENTING CELLS; BACTERIAL TOXINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EPITOPES; EXOTOXINS; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOCYTE ACTIVATION; NUCLEOCAPSID; SUPERANTIGENS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84898629953     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093598     Document Type: Article

References (52)

1. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S-I, et al. (2004) In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination. The Journal of Experimental Medicine 199: 815-824. (Pubitemid 38375201)
2. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, et al. (2002) Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance. The Journal of Experimental Medicine 196: 1627-1638. (Pubitemid 36026474)
3. Boscardin SB, Hafalla JCR, Masilamani RF, Kamphorst AO, Zebroski HA, et al. (2006) Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. The Journal of Experimental Medicine 203: 599-606.
4. Tacken PJ, de Vries IJM, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Reviews Immunology 7: 790-802. (Pubitemid 47480309)
5. Susumu S, Nagata Y, Ito S, Matsuo M, Valmori D, et al. (2008) Crosspresentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells. Cancer Science 99: 107-112. (Pubitemid 350239038)
6. Wang XH, Qin Y, Hu MH, Xie Y (2005) Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunology, Immunotherapy 54: 971-980. (Pubitemid 41187705)
7. Lee RS, Tartour E, van der Bruggen P, Vantomme V, Joyeux I, et al. (1998) Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. European Journal of Immunology 28: 2726-2737. (Pubitemid 28425231)
8. Freire T, Zhang X, Dériaud E, Ganneau C, Vichier-Guerre S, et al. (2010) Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant. Blood 116: 3526-3536.
9. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, et al. (2003) Phagosomes are competent organelles for antigen cross-presentation. Nature 425: 402-406. (Pubitemid 37187269)
10. Gagnon E, Duclos S, Rondeau C, Chevet E, Cameron PH, et al. (2002) Endoplasmic Reticulum-Mediated Phagocytosis Is a Mechanism of Entry into Macrophages. Cell 110: 119-131. (Pubitemid 34874611)
11. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C (2008) Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nature immunology 9: 558-566. (Pubitemid 351560525)
12. Ackerman AL, Kyritsis C, Tampé R, Cresswell P (2003) Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proceedings of the National Academy of Sciences 100: 12889-12894. (Pubitemid 37339995)
13. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, van Endert P, et al. (2003) ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425: 397-402. (Pubitemid 37187268)
14. Rock KL, Shen L (2005) Cross-presentation: underlying mechanisms and role in immune surveillance. Immunological reviews 207: 166-183. (Pubitemid 41415016)
15. Jegerlehner A, Tissot A, Lechner F, Sebbel P, Erdmann I, et al. (2002) A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20: 3104-3112.
16. Watts NR, Conway JF, Cheng N, Stahl SJ, Belnap DM, et al. (2002) The morphogenic linker peptide of HBV capsid protein forms a mobile array on the interior surface. EMBO Journal 21: 876-884. (Pubitemid 34206161)
17. Zlotnick A, Cheng N, Conway JF, Booy FP, Steven AC, et al. (1996) Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein. Biochemistry 35: 7412-7421.
18. Liu S, Tobias R, McClure S, Styba G, Shi Q, et al. (1997) Removal of endotoxin from recombinant protein preparations. Clinical Biochemistry 30: 455-463. (Pubitemid 27418541)
19. Dickgreber N, Stoitzner P, Bai Y, Price KM, Farrand KJ, et al. (2009) Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapy. Journal of Immunology 182: 1260-1269.
20. Proft T, Schrage B, Fraser JD (2007) The cytokine response to streptococcal superantigens varies between individual toxins and between individuals: implications for the pathogenesis of group A streptococcal diseases. Journal of Interferon & Cytokine Research 27: 553-557. (Pubitemid 47122714)
21. Gorga JC, Horejsi V, Johnson DR, Raghupathy R, Strominger JL (1987) Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. The Journal of biological chemistry 262: 16087-16094. (Pubitemid 17165204)
22. Gehring AJ, Sun D, Kennedy PTF, Nolte-'t Hoen E, Lim SG, et al. (2007) The level of viral antigen presented by hepatocytes influences CD8 T-cell function. Journal of Virology 81: 2940-2949. (Pubitemid 46447057)
23. Lau GKK, Suri D, Liang R, Rigopoulou EI, Thomas MG, et al. (2002) Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122: 614-624. (Pubitemid 34173812)
24. Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, et al. (2005) Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity. Hepatology 42: 1028-1036. (Pubitemid 43112669)
25. Mayer S, Laumer M, Mackensen A, Andreesen R, Krause SW (2002) Analysis of the Immune Response against Tetanus Toxoid: Enumeration of Specific T Helper Cells by the Elispot Assay. Immunobiology 205: 282-289. (Pubitemid 34846737)
26. Schatz DET, Ottendorfer E, Jodoin E, Barrett D, Atkinson M (1998) Aging and the Immune Response to Tetanus Toxoid: Diminished Frequency and Level of Cellular Immune Reactivity to Antigenic Stimulation. Clinical and Diagnostic Laboratory Immunology 5: 894-896. (Pubitemid 28519270)
27. Mizukoshi E, Sidney J, Livingston B, Ghany M, Hoofnagle JH, et al. (2004) Cellular Immune Responses to the Hepatitis B Virus Polymerase. The Journal of Immunology 173: 5863-5871. (Pubitemid 39392177)
28. Arcus VL, Proft T, Sigrell JA, Baker HM, Fraser JD, et al. (2000) Conservation and variation in superantigen structure and activity highlighted by the threedimensional structures of two new superantigens from Streptococcus pyogenes. Journal of molecular biology 299: 157-168.
29. Basha G, Lizee G, Reinicke AT, Seipp RP, Omilusik KD, et al. (2008) MHC class I endosomal and lysosomal trafficking coincides with exogenous antigen loading in dendritic cells. PLoS ONE [Electronic Resource] 3: e3247.
30. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C (2007) Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316: 612-616. (Pubitemid 46683149)
31. Gromme M, Uytdehaag FG, Janssen H, Calafat J, van Binnendijk RS, et al. (1999) Recycling MHC class I molecules and endosomal peptide loading. Proceedings of the National Academy of Sciences of the United States of America 96: 10326-10331. (Pubitemid 29422557)
32. Bachmann MF, Zinkernagel RM (1997) Neutralizing antiviral B cell responses. Annual review of immunology 15: 235-270. (Pubitemid 27169281)
33. Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, et al. (1987) Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330: 381-384.
34. Cohen BJ, Richmond JE (1982) Electron microscopy of hepatitis B core antigen synthesized in E. coli. Nature 296: 677-679.
35. Stahl S, MacKay P, Magazin M, Bruce SA, Murray K (1982) Hepatitis B virus core antigen: synthesis in Escherichia coli and application in diagnosis. Proceedings of the National Academy of Sciences of the United States of America 79: 1606-1610. (Pubitemid 12113317)
36. Bertoletti A, Maini MK (2000) Protection or damage: a dual role for the virusspecific cytotoxic T lymphocyte response in hepatitis B and C infection? Current opinion in immunology 12: 403-408. (Pubitemid 30410344)
37. Menne S, Tennant BC, Gerin JL, Cote PJ (2007) Chemoimmunotherapy of Chronic Hepatitis B Virus Infection in the Woodchuck Model Overcomes Immunologic Tolerance and Restores T-Cell Responses to Pre-S and S Regions of the Viral Envelope Protein. Journal of Virology 81: 10614-10624. (Pubitemid 47463335)
38. Akbar SMF, Chen S, Al-Mahtab M, Abe M, Hiasa Y, et al. (2012) Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antiviral research 96: 59-64.
39. Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, et al. (1993) Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis Bimmune donor. Gastroenterology 104: 1818-1821. (Pubitemid 23235477)
40. Heathcote J, McHutchison J, Lee S, Tong M, Benner K, et al. (1999) A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 30: 531-536. (Pubitemid 29357521)
41. Lazdina U, Cao T, Steinbergs J, Alheim M, Pumpens P, et al. (2001) Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells. Journal of Virology 75: 6367-6374. (Pubitemid 32578155)
42. Storni T, Lechner F, Erdmann I, Bachi T, Jegerlehner A, et al. (2002) Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. Journal of immunology (Baltimore, Md : 1950) 168: 2880-2886. (Pubitemid 34211668)
43. Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, et al. (2010) Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 116: 2277-2285.
44. Trumpfheller C, Finke JS, Lopez CB, Moran TM, Moltedo B, et al. (2006) Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. The Journal of Experimental Medicine 203: 607-617.
45. Lunde E, Munthe LA, Vabo A, Sandlie I, Bogen B (1999) Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat Biotech 17: 670-675. (Pubitemid 29316145)
46. Lunde E, Rasmussen IB, Eidem JK, Gregers TF, Western KH, et al. (2001) 'Troy-bodies': antibodies as vector proteins for T cell epitopes. Biomolecular Engineering 18: 109-116. (Pubitemid 32889610)
47. Lunde E, Western KH, Rasmussen IB, Sandlie I, Bogen B (2002) Efficient Delivery of T Cell Epitopes to APC by Use of MHC Class II-Specific Troybodies. The Journal of Immunology 168: 2154-2162. (Pubitemid 34171814)
48. Broos K, Vanlandschoot P, Maras M, Robbens J, Leroux-Roels G, et al. (2007) Expression, purification and characterization of full-length RNA-free hepatitis B core particles. Protein Expression and Purification 54: 30-37. (Pubitemid 46656468)
49. Cooper A, Tal G, Lider O, Shaul Y (2005) Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. Journal of Immunology 175: 3165-3176. (Pubitemid 41170538)
50. Ackerman AL, Kyritsis C, Tampe R, Cresswell P (2005) Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nature immunology 6: 107-113. (Pubitemid 40136702)
51. Song R, Harding CV (1996) Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. Journal of immunology (Baltimore, Md : 1950) 156: 4182-4190.
52. Win SJ, Ward VK, Dunbar PR, Young SL, Baird MA (2011) Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunology and cell biology 89: 681-688.